ATS Gets $3M in Cancer Funding

Xconomy San Diego — 

The National Cancer Institute awarded $3 million to San Diego’s Advanced Targeting Systems, a company that develops and provides products for neuroscience researchers, and has developed technology for targeting specific types of cells. In 1997, for example, ATS developed SP-SAP, a reagent that eliminates specific pain transmission neurons that propagate chronic pain signals. In a statement released today, ATS says it plans to use the institute funding to advance SP-SAP for the next two years to initiate clinical trials for treating cancer pain.

By posting a comment, you agree to our terms and conditions.

Comments are closed.